Eli Lilly USA - Search News

Eli Lilly, Zepbound and Mounjaro

Eli Lilly is considering offering more Zepbound doses in vials at lower cost

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning to compounding pharmacies that make cheaper copies of Zepbound, since the branded treatment has been too costly and, up until recently, has been in shortage.

Yahoo · 1d

Eli Lilly’s Zepbound and Mounjaro Sales Missed Estimates Again. The Wobble’s Looking Serious.

Eli Lilly can’t seem to recover from its GLP-1 stumble. Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates. It was the second consecutive miss for the two closely watched obesity and Type 2 diabetes drugs,

MarketWatch on MSN · 1d

Mounjaro and Zepbound sales disappoint, and Eli Lilly’s stock is dropping

Eli Lilly’s stock was set to suffer its worst day in four years after sales of diabetes and obesity drugs Mounjaro and Zepbound missed expectations.

JD Supra14h

Lilly v. FDA: Two Stories Collide to Make this GLP-1 Case a Tale of Our Time

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...

1don MSN

Eli Lily cuts 2024 revenue guidance by $400M, shares sink 8%

The London Metal Exchange is in its final stages to approve Hong Kong as the main warehousing network for its metals.

12h

Eli Lilly: Big 2025 Ahead, But Execution Risks Exist

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

11h

Balanced Outlook with Long-Term Optimism: Steve Scala Maintains Buy Rating for Eli Lilly & Co

TD Cowen analyst Steve Scala reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $900.00.Stay ...

조선일보1d

Eli Lilly CEO confirms oral obesity drug Phase 3 results expected in Q2

Eli Lilly CEO confirms oral obesity drug Phase 3 results expected in Q2 Eli Lillys CEO updates on drug trials amid mixed ...

The Financial Times5d

Eli Lilly in advanced talks to buy US cancer biotech for up to $2.5bn

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Eli Lilly, the world’s largest drugmaker by market value, is in advanced talks to buy cancer-focused ...

Eli Lilly & Co: Strong Long-Term Growth Prospects Amid Q4 Revenue Shortfall Justify Buy Rating

Bank of America Securities analyst Tim Anderson maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price ...

usaherald12h

City of Meriden Sues Drug Makers Over Alleged Insulin Pricing Scheme

The city of Meriden, Connecticut, filed a lawsuit in federal court on Monday, accusing 20 companies, including major drug manufacturers such as CVS Health Corp., Eli Lilly and Co., and Novo Nordisk ...

Medindia3h

FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's ...

PipelineReview.com2d

Lilly to acquire Scorpion Therapeutics’ mutant-selective PI3Kα inhibitor program

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor ...

Hosted on MSN18h

Eli Lilly Gets Wall Street Backing After Tuesday’s Turmoil, Stock Rises Premarket As Retail Stays Bullish

Eli Lilly & Co. (LLY) shares rose 0.3% premarket Wednesday, bouncing slightly after Tuesday's steep 6% plunge — the worst ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results